641571-12-2

Basic information

• Product Name: 3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzonitrile
• Synonyms: 3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzonitrile;-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzonitrile;Nilotinib Impurity 12;Benzonitrile,3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)-
• CAS NO: 641571-12-2
• Molecular Formula: C₁₂H₈F₃N₃
• Molecular Weight: 0
• Product Categories: API intermediates
• Mol File: 641571-12-2.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzonitrile(641571-12-2)
• EPA Substance Registry System: 3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzonitrile(641571-12-2)

Safety Data

• Hazardous Substances Data: 641571-12-2(Hazardous Substances Data)

Usage

Description

3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzonitrile is an organic compound characterized by its imidazole and trifluoromethylbenzonitrile moieties. It is a versatile molecule with potential applications in various fields due to its unique structural features and reactivity.

Uses

Used in Pharmaceutical Industry:
3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzonitrile is used as a reagent for the synthesis of small molecular inhibitors. These inhibitors are designed to target the catalytic domains of protein kinases that are not in an active conformation. By inhibiting these protein kinases, the compound can potentially play a role in the development of therapeutics for various diseases, including cancer and other conditions involving abnormal cell signaling.

Upstream product

• 822-36-6 4-methyl-1H-imidazole 
• 149793-69-1 3-fluoro-5-trifluoromethyl-benzonitrile 
• 693-98-1 2-methylimidazole 

Downstream Products

• 641571-13-3 3-(4-methyl-imidazol-1-yl)-5-trifluoromethylbenzoic acid 
• 917391-28-7 3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzamide 

Relevant articles and documents

PROTEIN KINASE INHIBITORS

The present invention relates to compounds of the following formula (I) and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the present invention thus also includes the preparation of compounds of formula (I), their uses, in particular in the inhibition of protein kinases which are implicated for example in numerous diseases such as cancers or immune system disorders.

A type-ii kinase inhibitor capable of inhibiting the T315I "Gatekeeper" mutant of Bcr-Abl

The second generation of Bcr-Abl inhibitors nilotinib, dasatinib, and bosutinib developed to override imatinib resistance are not active against the T315I "gatekeeper" mutation. Here we describe a type-II T315I inhibitor 2 (GNF-7), based upon a 3,4-dihydr

CHEMICAL COMPOUNDS

The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof, of the formula (I): which possess B-Raf inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.